DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Public ClinicalTrials.gov record NCT03529110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
Study identification
- NCT ID
- NCT03529110
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 524 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2018 (Actual)
- Primary completion
- May 21, 2021 (Actual)
- Completion
- Aug 31, 2026 (Actual)
- Last update posted
- Oct 7, 2026
2018 – 2026
United States locations
- U.S. sites
- 28
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology Oncology | Los Angeles | California | 90095 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| University of California San Francisco | San Francisco | California | 94115 | — |
| Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| Washington Cancer Institute | Washington D.C. | District of Columbia | 20010 | — |
| Florida Cancer Specialists-Broadway | Fort Myers | Florida | 33916 | — |
| Florida Cancer Specialists NORTH | St. Petersburg | Florida | 33705 | — |
| Piedmont Cancer Institute, PC | Atlanta | Georgia | 30318 | — |
| Loyola University Health System | Maywood | Illinois | 60153 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| North Shore Hematology Oncology Associates, PC | East Setauket | New York | 11733 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Wake Forest University Baptist Medical Center | Winston-Salem | North Carolina | 27157 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45267 | — |
| Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Dayton Physicians, LLC | Kettering | Ohio | 45409 | — |
| Magee-Womens Hospital of UPMC | Pittsburgh | Pennsylvania | 15213 | — |
| Tennessee Oncology- St Thomas Location | Nashville | Tennessee | 37205 | — |
| Vanderbilt Breast Center at One Hundred Oaks | Nashville | Tennessee | 37232 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Houston Methodist Hospital / Houston Methodist Cancer Center | Houston | Texas | 77030 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Millennium Oncology | Houston | Texas | 77090 | — |
| The University of Texas Health Science Center at Tyler | Tyler | Texas | 75708 | — |
| MultiCare Health System Institute for Research and Innovation | Auburn | Washington | 98001 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 136 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03529110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 7, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03529110 live on ClinicalTrials.gov.